Ady 1995.

Clinical features and settings	Inclusion period: June 1989 to December 1992. Patient population: 37 patients with newly diagnosed stage 4 neuroblastoma of which 27 were included in this study; nine children were excluded because of unavailable data at mid‐course and one other for lack of ¹²³I‐MIBG uptake (negative scan). Consecutive series: yes. Diagnostic work‐up: clinical examination, bone marrow status and all imaging data: at least CT scan and ¹²³I‐MIBG scan, and in certain cases bone scan, X‐rays and MRI scan to explore metastases to bone and bone marrow, liver, distant lymph nodes, skin, lungs and central nervous system. Time spans symptoms‐index test, symptoms‐reference standard and index test‐reference standard: n.r. Treatment between index test‐reference standard: n.r.
Participants	Included patients: 27 children with neuroblastoma at first diagnosis. Median age at diagnosis: n.r.; mean age at diagnosis: 37 months (range 10 to 97 months). Sex distribution: 19 boys (70%), 8 girls (30%). INSS stage: all stage 4 neuroblastoma.
Study design	Cohort study. N.r. whether the study was retrospective or prospective.
Target condition and reference standard(s)	Target condition: newly diagnosed neuroblastoma. Reference standard: n.r. for the primary tumour. For metastases: bone marrow status by bone marrow cytology, bone histology (at least four samples) and immunocytology. In case of discrepant results from different methods, the most abnormal data were considered as definitive.
Index and comparator tests	Index test: ¹²³I‐MIBG scintigraphy. Radiofarmacon: ¹²³I‐MIBG. Dose: 3.7 MBq/kg, with a maximum of 110 MBq Collimator: low energy, high definition. Matrix: 256 x 1024 for WB scans and 256 x 256 for lateral views (4 mid‐frame). Acquisition protocol: anterior and posterior WB scans and lateral views of the head. Acquisition time: 2.2 to 26 hours after injection. Acquisition duration: 12 min/m for WB scans. Interfering medication: not reported. Thyroid prophylaxis: not reported. Positive test result: n.r. Number of observers: two independent specialists; to assess reproducibility of the method, images of 16/27 patients were interpreted independently by four investigators (including the previous two specialists). Expertise of investigators: n.r. Interobserver concordance: n.r.
Follow‐up	Median follow‐up: 18 months (range 1 to 52 months) after diagnosis.
Notes	Results were n.r. for ¹²³I‐MIBG scans at first diagnosis separately from ¹²³I‐MIBG scans during follow‐up. Contact information of the study authors: not available.